Mutant metabolic enzymes are at the origin of gliomas

Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within the isocitrate binding site (R132 of IDH1 an...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 69; no. 24; pp. 9157 - 9159
Main Authors Yan, Hai, Bigner, Darell D, Velculescu, Victor, Parsons, D Williams
Format Journal Article
LanguageEnglish
Published United States 15.12.2009
Subjects
Astrocytoma - enzymology
Astrocytoma - genetics
Central Nervous System Neoplasms - enzymology
Central Nervous System Neoplasms - genetics
Glioblastoma - enzymology
Glioblastoma - genetics
Humans
Isocitrate Dehydrogenase - genetics
Mutation
Online AccessGet full text

Cover

More Information
Summary:Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas. All mutations identified to date affect a single amino acid located within the isocitrate binding site (R132 of IDH1 and the analogous R172 residue of IDH2). IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Current Address: Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston TX
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-09-2650